Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critica! translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation.
Característiques principals
2014 PRECLINICAL RESEARCH FUNDING PRIORITIES
Drug Discovery - Target validation, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization-, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics
  • Biomarker Development - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.

    FUNDING MECHANISMS
  • Academic Program seeks to create and support innovative translational programs in academic medical centers and universities.
  • Biotechnology Development Program supports qualified scientific projects in existing, private, early-stage biotechnology companies. The ADDF will provide support for qualified projects in more advanced companies if a clear need for non-profit funding to support the project can be demonstrated and justified. Funding is typically made as a program-related investment.
  • Biotechnology Founders Technology Transfer Program supports academic programs that are eligible for technology transfer and the start-up of new biotechnology companies. Up to 35% of funds from these awards may be employed for expenses related to company formation, such as administrative, legal, patent and third-party vendor costs.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Convocatòria (URL)
    Convocatòria:
    http://www.alzdiscovery.org/assets/content/static/2014_Preclinical_Drug_Discovery_RFP.pdf
    Instruccions:
    http://www.alzdiscovery.org/assets/content/static/ADDF_APPLICATION_FORM_FINAL_July2013.pdf
    Dotació
    Average of 150,000 per year
    Durada
    1 year, with potential for future follow-on funding.
    In some cases, multi-year proposals can be considered.
    AVÍS IMPORTANT
    2014 QUARTERLY DEADLINES
    March 5
    June 5
    September 5
    December 5

    Interested applicants must first submit a Letter of Intent electronically via the ADDF website (www.alzdiscovery.org) before the deadline.

    Arxius

    Arxiu
    Request for Proposals